查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1507900

自体基质诱导软骨形成（AMIC）的全球市场

Autologous Matrix-Induced Chondrogenesis (AMIC)
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 214 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

自体基质诱导软骨形成 (AMIC) 的全球市场预计到 2030 年将达到 2.78 亿美元

预计2023年自体基质诱导软骨形成（AMIC）的全球市场规模为1.644亿美元，预计到2030年将达到2.78亿美元，在2023-2030年的分析期间复合年增长率为7.8%。胶原蛋白是本报告分析的细分市场之一，预计复合年增长率为 7.5%，到分析期结束时将达到 1.588 亿美元。分析期间，透明质酸细分市场的复合年增长率预计为 6.9%。

美国市场预估为5,280万美元，中国预期复合年增长率为9.9%。

预计 2023 年美国自体基质诱导软骨形成 (AMIC) 市场规模将达 5,280 万美元。中国作为全球第二大经济体，预计2030年市场规模将达2,610万美元，2023年至2030年复合年增长率为9.9%。其他值得注意的区域市场包括日本和加拿大，预计在分析期间复合年增长率分别为 6.4% 和 7.3%。在欧洲，德国的复合年增长率预计约为 8.1%。

全球自体基质诱导软骨形成 (AMIC) 市场 - 主要趋势和驱动因素总结

自体基质诱导软骨形成（AMIC）是一种创新的手术技术，旨在治疗关节软骨缺陷。这种手术技术结合了微骨折手术和生物相容性胶原蛋白膜的应用，微骨折手术在软骨下骨上形成小孔以刺激血流和细胞迁移。胶原蛋白膜提供了支持间质干细胞增生和分化为软骨细胞的支架。虽然 AMIC 主要用于膝关节，但它也可以应用于其他关节，如髋关节、踝关节和肩关节。该技术旨在修復软骨损伤、减轻疼痛并改善关节功能，为传统软骨修復方法（例如自体软骨细胞植入（ACI））提供一种侵入性较小的替代方案。

在 AMIC 手术中，首先使用关节镜手术或小型开放性手术来修復软骨缺损。分离受损的软骨后，底下的骨骼会产生微骨折，释放出富含干细胞的骨髓元素。然后将通常来自猪或牛的胶原蛋白膜放置在微骨折上并用纤维蛋白胶或缝线固定。这种膜不仅提供了保护新形成的软骨的物理屏障，而且还为干细胞增殖和分化创造了最佳环境。随着时间的推移，这些细胞会产生新的软骨组织，与现有软骨融合，促进长期关节健康。由于 AMIC 是微创手术，因此与更具侵入性的手术相比，恢復更快，术后不适也更少。

自体基质诱导软骨形成 (AMIC) 市场的成长受到多种因素的推动，这些因素反映了医疗技术的进步、关节损伤盛行率的增加以及对有效软骨修復解决方案的需求。关键驱动因素之一是运动伤害和骨关节炎的盛行率不断上升，增加了对能够恢復关节功能和减轻疼痛的创新治疗方法的需求。生物材料和外科技术的技术进步也促进了 AMIC 的采用。这是因为这些进步提高了手术的有效性和可靠性。此外，人口老化更容易发生关节退化，也导致软骨修復疗法的需求增加。向微创手术技术的转变进一步推动市场成长，患者寻求恢復时间更短、风险更低的手术。各地区的监管核准和有利的报销政策也支持 AMIC 的采用。总的来说，这些因素正在推动 AMIC 市场的扩张和创新，确保 AMIC 在临床实践中的持续发展和采用。

受访企业范例（28家知名企业）

  • Anika Therapeutics, Inc.
  • Arthro Kinetics Biotechnology GmbH
  • B. Braun Melsungen
  • CONMED Corporation
  • Geistlich Pharma AG
  • JRI Orthopaedics Ltd.
  • Matricel GmbH
  • Vericel Corporation
  • Zimmer Biomet Holdings, Inc.

目录

第一章调查方法

第 2 章执行摘要

  • 市场概况
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 拉丁美洲
  • 世界其他地区

第四章 比赛

简介目录
Product Code: MCP10423

Global Autologous Matrix-Induced Chondrogenesis (AMIC) Market to Reach US$278.0 Million by 2030

The global market for Autologous Matrix-Induced Chondrogenesis (AMIC) estimated at US$164.4 Million in the year 2023, is expected to reach US$278.0 Million by 2030, growing at a CAGR of 7.8% over the analysis period 2023-2030. Collagen, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$158.8 Million by the end of the analysis period. Growth in the Hyaluronic Acid segment is estimated at 6.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$52.8 Million While China is Forecast to Grow at 9.9% CAGR

The Autologous Matrix-Induced Chondrogenesis (AMIC) market in the U.S. is estimated at US$52.8 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$26.1 Million by the year 2030 trailing a CAGR of 9.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.4% and 7.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.1% CAGR.

Global Autologous Matrix-Induced Chondrogenesis (AMIC) Market - Key Trends & Drivers Summarized

Autologous Matrix-Induced Chondrogenesis (AMIC) is an innovative surgical technique developed to treat articular cartilage defects in joints. This procedure combines microfracture surgery, which involves creating small holes in the subchondral bone to stimulate blood flow and cell migration, with the application of a biocompatible collagen membrane. The membrane serves as a scaffold to support the growth and differentiation of mesenchymal stem cells into chondrocytes, which are the cells responsible for producing cartilage. AMIC is primarily used in the knee, but it can also be applied to other joints such as the hip, ankle, and shoulder. This technique aims to repair cartilage damage, reduce pain, and improve joint function, offering a less invasive alternative to traditional cartilage repair methods like autologous chondrocyte implantation (ACI).

The procedure for AMIC begins with arthroscopic or mini-open surgery to access the cartilage defect. After debriding the damaged cartilage, microfractures are created in the underlying bone to release bone marrow elements rich in stem cells. A collagen membrane, typically derived from porcine or bovine sources, is then placed over the microfractured area and secured with fibrin glue or sutures. This membrane not only provides a physical barrier to protect the newly forming cartilage but also creates an optimal environment for the stem cells to proliferate and differentiate. Over time, these cells generate new cartilage tissue that integrates with the existing cartilage, promoting long-term joint health. The minimally invasive nature of AMIC allows for quicker recovery times and less postoperative discomfort compared to more invasive procedures.

The growth in the Autologous Matrix-Induced Chondrogenesis (AMIC) market is driven by several factors, reflecting advancements in medical technology, increasing prevalence of joint injuries, and the demand for effective cartilage repair solutions. One significant driver is the rising incidence of sports injuries and osteoarthritis, which has heightened the need for innovative treatments that can restore joint function and alleviate pain. Technological advancements in biomaterials and surgical techniques have also contributed to the adoption of AMIC, as these improvements enhance the effectiveness and reliability of the procedure. Additionally, the growing aging population, which is more susceptible to joint degeneration, has led to increased demand for cartilage repair therapies. The shift towards minimally invasive surgical techniques further supports the market growth, as patients seek procedures with shorter recovery times and lower risks. Regulatory approvals and favorable reimbursement policies in various regions are also encouraging the adoption of AMIC. These factors collectively drive the expansion and innovation in the AMIC market, ensuring its continued evolution and adoption in clinical practice.

Select Competitors (Total 28 Featured) -

  • Anika Therapeutics, Inc.
  • Arthro Kinetics Biotechnology GmbH
  • B. Braun Melsungen
  • CONMED Corporation
  • Geistlich Pharma AG
  • JRI Orthopaedics Ltd.
  • Matricel GmbH
  • Vericel Corporation
  • Zimmer Biomet Holdings, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Increasing Prevalence of Joint Disorders to Fuel Growth in Autologous Matrix-Induced Chondrogenesis Market
    • Autologous Matrix-Induced Chondrogenesis (AMIC): A Prelude
    • Global Economic Update
    • Global Average Annual Brent Crude Oil Price (In US$ Per Barrel) for Years 2017 through 2024
    • Global Inflation Rates (In %) for the Years 2019 through 2024
    • World Economic Growth Projections (Real GDP, Annual % Change) for the Years 2020 Through 2024
    • Autologous Matrix-Induced Chondrogenesis (AMIC) - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • INFLUENCER/PRODUCT/TECHNOLOGY INSIGHTS
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • AMIC Holds Significance in Cartilage Repair Domain
    • Rise in Sports Participation and Increase in Sports-Related Injuries Augment Growth Prospects
    • Autologous Matrix-Induced Chondrogenesis (AMIC) in Ankle Repair: A Review
    • Growing Demand for Minimally-Invasive Surgeries to Propel Market Growth
    • Rise in Incidence of Osteoporosis to Benefit Market Growth
    • Global Osteoporosis Prevalence: Number of People with Osteoporosis in Millions by Select Country/Region for 2012 and 2023
    • Cellular Therapy as Lifeblood of Clinical Routines Targeting Cartilage Regeneration
    • AMIC: Highly Effective in Management of Focal Chondral Defects of the Knee
    • Assessment of Open & Arthroscopic Approaches for AMIC to Repair Cartilage Defects
    • MACI Solutions: Promising Options in Articular Cartilage Treatment
    • Aging Population and their Vulnerability to Various Bone and Joint Related Diseases and Disorders Drive Healthy Market Growth
    • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • Select Musculoskeletal Conditions - Percentage Breakdown by Age Group
    • Rise in Overweight Patients to Boost Prospects
    • Global Obesity Epidemic: Percentage of Overweight, Obese, and Severely Obese Adults for 2014 & 2025
    • Obesity Prevalence Rate (%) in Select Countries for the Years 2019 and 2030P
    • Changing Lifestyle Impacting Bone Health
    • Rising Healthcare Spending Augurs Well for the Market
    • World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Autologous Matrix-Induced Chondrogenesis (AMIC) Market Analysis of Annual Sales in US$ Thousand for Years 2017 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 4: World 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2017, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Collagen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Collagen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 7: World 13-Year Perspective for Collagen by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World for Years 2017, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Hyaluronic Acid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Hyaluronic Acid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 10: World 13-Year Perspective for Hyaluronic Acid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World for Years 2017, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Polyethylene Glycol (PEG) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Polyethylene Glycol (PEG) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 13: World 13-Year Perspective for Polyethylene Glycol (PEG) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World for Years 2017, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Polylactic-Co-Glycolic Acid (PGLA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Polylactic-Co-Glycolic Acid (PGLA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 16: World 13-Year Perspective for Polylactic-Co-Glycolic Acid (PGLA) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World for Years 2017, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Materials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Materials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 19: World 13-Year Perspective for Other Materials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World for Years 2017, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Autologous Matrix-Induced Chondrogenesis (AMIC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 22: USA 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2024 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 25: Canada 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2024 & 2030
  • JAPAN
    • TABLE 26: Japan Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Japan Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 28: Japan 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2024 & 2030
  • CHINA
    • TABLE 29: China Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: China Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 31: China 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2024 & 2030
  • EUROPE
    • Autologous Matrix-Induced Chondrogenesis (AMIC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 34: Europe 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2017, 2024 & 2030
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 37: Europe 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2024 & 2030
  • FRANCE
    • TABLE 38: France Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: France Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 40: France 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2024 & 2030
  • GERMANY
    • Autologous Matrix-Induced Chondrogenesis (AMIC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 41: Germany Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Germany Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 43: Germany 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2024 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Italy Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 46: Italy 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2024 & 2030
  • UNITED KINGDOM
    • Autologous Matrix-Induced Chondrogenesis (AMIC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 47: UK Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: UK Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 49: UK 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2024 & 2030
  • SPAIN
    • TABLE 50: Spain Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Spain Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 52: Spain 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2024 & 2030
  • RUSSIA
    • TABLE 53: Russia Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Russia Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 55: Russia 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2024 & 2030
  • REST OF EUROPE
    • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Rest of Europe Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 58: Rest of Europe 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2024 & 2030
  • ASIA-PACIFIC
    • Autologous Matrix-Induced Chondrogenesis (AMIC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 61: Asia-Pacific 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2024 & 2030
  • LATIN AMERICA
    • TABLE 62: Latin America Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Latin America Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 64: Latin America 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2024 & 2030
  • REST OF WORLD
    • TABLE 65: Rest of World Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Rest of World Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 67: Rest of World 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2024 & 2030

IV. COMPETITION